Evidence map›Paper›PMID 36899319›Full record

Trial reportBMC cancer2023

Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer.

Yuanlong Gu, Qianjin Hua, Zhipeng Li, Xingli Zhang, Changjie Lou, Yangfen Zhang, Wei Wang, Peiyuan Cai, Juan Zhao

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Catching pancreatic cancer early: Are we there yet?Journal of the National Cancer Center · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuanlong GuDepartment of Interventional Oncology, Municipal Hospital Affiliated to Taizhou University, Taizhou, China.
Qianjin HuaDepartment of Interventional Oncology, Municipal Hospital Affiliated to Taizhou University, Taizhou, China.
Zhipeng LiSchool of Medicine, Taizhou University, Taizhou, 318000, Zhejiang, China.
Xingli ZhangBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, China.
Changjie LouBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, China.
Yangfen ZhangSchool of Medicine, Taizhou University, Taizhou, 318000, Zhejiang, China.
Wei WangDepartment of Interventional Oncology, Municipal Hospital Affiliated to Taizhou University, Taizhou, China.
Peiyuan CaiDepartment of Interventional Oncology, Municipal Hospital Affiliated to Taizhou University, Taizhou, China.
Juan ZhaoBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, China. zhaojuanhayida@163.com.

Funding

Haiyan Fund Project of Harbin Medical University Cancer Hospital JJZD2020-03Health Commission of Heilongjiang 2019-060Zhejiang Provincial Health Planning Commission Fund 2020389903Zhejiang Provincial Natural Science Foundation of China LGC22H160012
6 · The paper itself

Abstract

backgroundAn early diagnosis of pancreatic cancer (PC) is extremely difficult because of the lack of sensitive liquid biopsy methods and effective biomarkers. We attempted to evaluate whether circulating inflammatory marker could complement CA199 for the detection of early-stage PC.

methodsWe enrolled 430 patients with early-stage PC, 287 patients with other pancreatic tumors (OPT), and 401 healthy controls (HC). The patients and HC were randomly divided into a training set (n = 872) and two testing sets (n

resultsCirculating fibrinogen, neutrophils, and monocytes in patients with PC were significantly higher while circulating albumin, prealbumin, lymphocytes, and platelets of patients with PC were significantly lower compared to those of HC and OPT (all P < 0.05). The fibrinogen-to-albumin (FAR), fibrinogen-to-prealbumin (FPR), neutrophil-to-lymphocyte (NLR), platelet-to-lymphocyte (PLR), monocyte-to-lymphocyte (MLR), and fibrinogen-to-lymphocyte (FLR) ratios were significantly higher while the prognostic nutrition index values (PNI) were lower in patients with PC than in HC and OPT (all P < 0.05). Combining the FAR, FPR, and FLR with CA199 exhibited the best diagnostic value for distinguishing patients with early-stage PC from HC with an area under the curve (AUC) of 0.964, and for distinguishing patients with early-stage PC from OPT with an AUC of 0.924 in the training sets. In the testing set, compared with HC, the combination markers had powerful efficiency for PC with an AUC 0.947 and AUC 0.942 when comparing PC with OPT. The AUC was 0.915 for the combination of CA199, FAR, FPR, and FLR for differentiating between patients with pancreatic head cancer (PHC) and other pancreatic head tumors (OPHT), and 0.894 for differentiating between patients with pancreatic body and tail cancer (PBTC) and other pancreatic body and tail tumors (OPBTT).

conclusionA combination of FAR, FPR, FLR, and CA199 may serve as a potential non-invasive biomarker for differentiating early-stage PC from HC and OPT, especially early-stage PHC.

Indexed as

Pancreatic NeoplasmsPrealbuminBiomarkers, TumorFibrinogenHumansLymphocytesNeutrophilsPrognosisRetrospective StudiesBiomarkers, TumorFibrinogenPrealbuminDiagnosisEarly-stage pancreatic cancerFARFLRFPRInflammatory

Identifiers

PMID36899319
PMCPMC9999638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.